FRATES JAMES M
Reporting owner on Forms 3, 4 and 5, CIK 1235598.
FRATES JAMES M reported on 1 issuer in 1 filing, the latest a Form 4 filed 2026-11-12.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| AMLX · Amylyx Pharmaceuticals, Inc.CIK 1658551 | officer (Chief Financial Officer) | 1 | 2026-11-12 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-10 | M exercised | +20,000 | $6.88 | 253,625 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-10 | S sold | -12,800 | $30.3209 | 240,825 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-10 | S sold | -7,200 | $30.9698 | 233,625 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Stock Option (right to buy), derivative | 2026-11-10 | M exercised | -20,000 | $0 | 323,835 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-09 | M exercised | +20,000 | $6.88 | 253,625 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-09 | S sold | -7,700 | $29.3887 | 245,925 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock | 2026-11-09 | S sold | -12,300 | $30.1105 | 233,625 | Form 4 |
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock, holding | 100,000 | Form 4 | ||||
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock, holding | 15,459 | Form 4 | ||||
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock, holding | 11,072 | Form 4 | ||||
| AMLX · Amylyx Pharmaceuticals, Inc.Common Stock, holding | 40,000 | Form 4 | ||||
| AMLX · Amylyx Pharmaceuticals, Inc.Stock Option (right to buy), derivative | 2026-11-09 | M exercised | -20,000 | $0 | 343,835 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001193125-26-458247 | Amylyx Pharmaceuticals, Inc. | 2026-11-12 |